Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China
暂无分享,去创建一个
Ming Yan | Wei Li | Yongmei Yin | Xiang Huang | T. Sun | Xinyu Wu | Yueyin Pan | Min Yan | Hongfei Gao | Nan Jin | Hongfei Gao | Qianjun Chen | Chunfang Hao | Yanxia Zhao | Xinhua Han | Kun Wang | Wei Li | N. Jin
[1] Frederick M. Howard,et al. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database , 2023, JAMA oncology.
[2] S. Loi,et al. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 , 2022, Breast.
[3] S. Loi,et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Lu Gan,et al. Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2− advanced breast cancer in real-world clinical practice , 2022, Annals of translational medicine.
[5] R. Haidinger,et al. Expert Discussion: Highlights from ABC6: Bridging the Gap and Insights in This First Virtual ABC Conference and from 10 Years ABC Consensus , 2021, Breast Care.
[6] A. Schneeweiss,et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.
[7] S. Wang,et al. 228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) , 2021, Annals of Oncology.
[8] B. Shao,et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis , 2021, Anti-cancer drugs.
[9] A. Chinnaiyan,et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination , 2021, Nature Medicine.
[10] Ting Li,et al. Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[11] A. Bardia,et al. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. , 2020, Future oncology.
[12] C. Perou,et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Gnant,et al. Breast cancer , 2019, Nature Reviews Disease Primers.
[14] H. Iwata,et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.
[15] K. Gelmon,et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up , 2019, Breast Cancer Research and Treatment.
[16] S. Loi,et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.
[17] M. Ellis,et al. CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.
[18] C. Compton,et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.
[19] F. Penault-Llorca,et al. Ki67 assessment in breast cancer: an update. , 2017, Pathology.
[20] Ewout W Steyerberg,et al. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints , 2014, BMC Medical Research Methodology.
[21] Wanqing Chen,et al. Breast cancer in China. , 2014, The Lancet. Oncology.
[22] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[23] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[24] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.